Alzheimer's disease

JPM: Biotech, VC execs on where the industry should look beyond cancer
JPM: Biotech, VC execs on where the industry should look beyond cancer
Fierce Biotech
oncology
cancer
Alzheimer's disease
diabetes
venture capital
JPMHC 2020
Flag link:
Analysts tip Biogen to file for aducanumab approval within weeks
Analysts tip Biogen to file for aducanumab approval within weeks
Fierce Biotech
Biogen
Alzheimer's disease
aducanumab
FDA
Flag link:
JPM: Already prepping for Alzheimer's launch, Biogen scouts 'top talent' and talks pricing
JPM: Already prepping for Alzheimer's launch, Biogen scouts 'top talent' and talks pricing
Fierce Pharma
Biogen
Alzheimer's disease
drug pricing
aducanumab
JPMHC 2020
Flag link:
Biogen makes another Alzheimer's bet, paying Pfizer $75M for early-phase drug
Biogen makes another Alzheimer's bet, paying Pfizer $75M for early-phase drug
Fierce Biotech
Biogen
Alzheimer's disease
Pfizer
PF-05251749
Flag link:
We May Be One Step Closer To A Vaccine Against Alzheimer’s Disease
We May Be One Step Closer To A Vaccine Against Alzheimer’s Disease
Forbes
vaccines
Alzheimer's disease
Flag link:
3 Pharma & Biotech Pipeline Areas to Keep an Eye on in 2020
3 Pharma & Biotech Pipeline Areas to Keep an Eye on in 2020
Yahoo/Zacks.com
Alzheimer's disease
Medical Marijuana
Rare Diseases
Flag link:
Biogen and the desperation of a need for Alzheimer's drugs
Biogen and the desperation of a need for Alzheimer's drugs
Fierce Biotech
Biogen
FDA
Alzheimer's disease
aducanumab
Flag link:
After Recent Tau Failure, Biogen Licenses Tau Therapeutic from Ionis for Alzheimer's Disease
After Recent Tau Failure, Biogen Licenses Tau Therapeutic from Ionis for Alzheimer's Disease
BioSpace
Biogen
Alzheimer's disease
IONIS-MAPTRx
Ionis Pharmaceuticals
Flag link:
Biogen chalks up another failure, but investors' eyes remain firmly on Alzheimer's
Biogen chalks up another failure, but investors' eyes remain firmly on Alzheimer's
Fierce Biotech
Biogen
Alzheimer's disease
aducanumab
progressive supranuclear palsy
gosuranemab
clinical trials
Flag link:
Grifols says trial shows positive effects in slowing Alzheimer's
Grifols says trial shows positive effects in slowing Alzheimer's
Reuters
Grifols
Alzheimer's disease
clinical trials
Flag link:
Biohaven Pharma to continue late-stage study of Alzheimer's treatment
Biohaven Pharma to continue late-stage study of Alzheimer's treatment
Reuters
Biohaven Pharmaceuticals
Alzheimer's disease
troriluzole
Flag link:
Biogen Points to Enrollment and Dosing to Explain Alzheimer’s Results
Biogen Points to Enrollment and Dosing to Explain Alzheimer’s Results
Xconomy
Biogen
Alzheimer's disease
aducanumab
Worldwide Clinical Trials
Flag link:
The clearest picture of Biogen's Alzheimer's drug is still fuzzy
The clearest picture of Biogen's Alzheimer's drug is still fuzzy
Biopharma Dive
Biogen
Alzheimer's disease
clinical trials
aducanumab
Flag link:
New Biogen data showed no major safety issues for its Alzheimer's drug
New Biogen data showed no major safety issues for its Alzheimer's drug
Reuters
Biogen
safety
Alzheimer's disease
aducanumab
clinical trials
Flag link:
6 Experimental Alzheimer’s Disease Diagnostics Projects Get Funding Boost
6 Experimental Alzheimer’s Disease Diagnostics Projects Get Funding Boost
Xconomy
Alzheimer's disease
diagnostics
DiamiR Biosciences
RetiSpec
Flag link:
What to watch as Biogen presents its all-important Alzheimer's data
What to watch as Biogen presents its all-important Alzheimer's data
Biopharma Dive
Biogen
clinical trials
Alzheimer's disease
aducanumab
Flag link:
Biogen’s stock could fall 10% on new Alzheimer’s drug data this week, top analyst says
Biogen’s stock could fall 10% on new Alzheimer’s drug data this week, top analyst says
CNBC
Biogen
Alzheimer's disease
aducanumab
Flag link:
Analyst: Biogen's aducanumab is not getting approved absent a deus ex machina
Analyst: Biogen's aducanumab is not getting approved absent a deus ex machina
Fierce Biotech
Biogen
aducanumab
FDA
Alzheimer's disease
Flag link:
Why Biogen's Recent Rebound May Not Last -- at Least for Now
Why Biogen's Recent Rebound May Not Last -- at Least for Now
Motley Fool
Biogen
MS
multiple sclerois
Alzheimer's disease
Tecfidera
aducanumab
Flag link:
Biogen’s top scientist nearly dares FDA not to approve Alzheimer’s drug
Biogen’s top scientist nearly dares FDA not to approve Alzheimer’s drug
Stat
Biogen
aducanumab
FDA
Alzheimer's disease
Flag link:

Pages